How to Facilitate Advisory Boards in Pharma

Definition

Advisory board facilitation in the pharmaceutical industry is the discipline of designing, moderating, and extracting actionable conclusions from meetings between a pharmaceutical company and a panel of external experts — typically KOLs (Key Opinion Leaders), specialist physicians, or clinical researchers. Unlike a presentation or symposium, a functional advisory board requires participants to generate original input, not passively receive information. Professional facilitation is the factor that determines whether a session produces insights that modify strategic decisions or merely validates preexisting positions without contributing new value.

In Latin America, advisory boards have become a central tool for medical affairs teams. However, facilitation quality varies significantly between providers and among pharmaceutical companies themselves, generating a wide range of outcomes — from sessions that transform product strategies to meetings that consume budget without producing usable information.

Why it matters

Advisory boards represent one of the most significant investments in medical affairs. A typical session involves 8 to 15 experts, with costs covering professional honoraria, travel logistics, accommodation, material preparation, and organizing team time. The total cost of an in-person advisory board in Latin America ranges from USD 15,000 to USD 60,000 depending on participant numbers and logistical complexity.

However, multiple industry studies indicate that between 40% and 60% of advisory boards fail to generate insights that modify subsequent strategic decisions. This figure implies that a substantial proportion of the investment is lost not due to lack of qualified experts, but due to deficiencies in session design and facilitation.

The main causes of this deficit are:

Sessions designed as one-way presentations disguised as consultation, where KOLs listen more than they contribute
Absence of a trained facilitator to manage group dynamics and ensure equitable participation
Questions too broad that generate rambling or too narrow that limit discussion to binary responses
Lack of a structured system for capturing and synthesizing insights generated during the session
Failure to differentiate between validation advisory boards (confirming a hypothesis) and exploration advisory boards (discovering new perspectives), which confuses objectives and methodology
Absence of post-session follow-up communicating to participants the impact of their contributions

Components of effective facilitation

A professionally facilitated advisory board requires substantial work before, during, and after the session. The essential components are:

Objective design linked to decisions — Before any logistical aspect, define precisely which decisions depend on the advisory board's output. Each discussion question should link to a concrete pending decision within the medical affairs, marketing, or market access team. An advisory board without linked decisions is an expensive conversation without a destination
Participant selection and briefing — Identify KOLs whose clinical experience is directly relevant to the specific topic, not just high-profile KOLs who participate in multiple advisory boards simultaneously. Send pre-read materials at least 10 days in advance so participants arrive with formed opinions, not improvising on data they see for the first time
Session structure — Alternate between short context presentations (15 minutes maximum each), guided discussions with specific questions, and prioritization exercises. The recommended ratio is 30% presentation and 70% discussion. Sessions that invert this ratio generate significantly fewer actionable insights
Active facilitation techniques — Include round-robin to ensure all participants contribute (not just the most vocal), anonymous voting for topics where social pressure could bias responses, divergence-convergence techniques to explore options broadly before prioritizing, and explicit management of disagreements as a source of valuable information rather than conflicts to avoid
Structured insight capture — Assign a dedicated team to document relevant verbatims, consensus points, areas of disagreement, and specific recommendations in real time. The synthesis should be delivered within 48 hours of the session, while the discussion remains fresh for reviewers
Post-session follow-up with loop closure — Communicate to participants within 30 days how their recommendations were evaluated and which were incorporated into decision-making. This loop closure sustains long-term KOL engagement and improves participation quality in future advisory boards

Types of advisory boards

Not all advisory boards serve the same purpose. Differentiating between types allows selecting the appropriate facilitation methodology:

Validation advisory boards — Seek to confirm or refute a specific hypothesis with expert opinion. Require direct questions and consensus metrics
Exploration advisory boards — Seek to discover unanticipated perspectives. Require open questions and facilitation techniques that allow emergence of unexpected ideas
Design advisory boards — Seek to co-create solutions with experts. Require collaborative exercises and prototypes for discussion
Regulatory advisory boards — Seek input on registration or market access strategies. Require specific legal structure and compliance documentation

Who needs it

Professional advisory board facilitation is used by:

Medical affairs teams organizing national, regional, or global advisory boards as part of their KOL engagement strategy
Medical directors needing external scientific input for pipeline, clinical development, or therapeutic positioning decisions
Market access teams requiring clinical perspectives on therapeutic value, comparators, and pricing strategies
Product managers seeking to validate positioning strategies, key messages, or launch plans with independent experts
Pharmacovigilance teams requiring expert opinion on safety signals or risk mitigation strategies

Common mistakes

Turning the advisory board into a symposium — If KOLs listen more than they speak, the session is not an advisory board. When 70% of the time is dedicated to company presentations, participants assume a passive role that does not generate the input justifying the investment
No external facilitator — When a company employee moderates, KOLs tend to filter their opinions and avoid contradicting the company's position. An independent facilitator obtains more direct responses and reduces courtesy bias
Generic questions that do not generate concrete discussion — Asking a panel of oncologists what they think about a treatment is too broad to generate actionable insights. Asking what criteria they use to decide between two treatment lines for a specific clinical profile generates concrete discussion and implementable recommendations
Not closing the loop with participants — KOLs who never receive feedback on the impact of their participation perceive the session as a formality without consequences and progressively reduce their commitment level or decline to participate
Agenda overload — Attempting to cover 8 topics in a 4-hour session produces superficial discussions on all of them. Three well-worked topics generate more value than eight superficially touched topics

How Leaderlix Health approaches it

Leaderlix Health designs and facilitates advisory boards for pharmaceutical companies in Latin America, with a focus on maximizing the quality of scientific input and linking it directly to business decisions. The process includes objective design linked to pending decisions, briefing material preparation for participants, professional in-session facilitation with group dynamics techniques adapted to the advisory board type, and insight synthesis delivered within 48 hours. Clients such as Bayer, Novartis, Pfizer, Galderma, and Abbott use Leaderlix Health facilitation services for both in-person and virtual advisory boards across multiple therapeutic areas and markets in the region.